Avidicure is pioneering an entirely new triple agonistic antibody modality, 'Actibody', designed to safely deliver targeted and potent monotherapy for patients, with broad applicability in oncology and autoimmune diseases
Avidicure is pioneering an entirely new triple agonistic antibody modality, 'Actibody', designed to safely deliver targeted and potent monotherapy for patients, with broad applicability in oncology and autoimmune diseases.